The present disclosure relates to surgical implant systems, including implants, instruments, and methods for installing an implant. Specifically, the present disclosure relates to systems and methods for securing a glenoid implant to a glenoid.
Surgical procedures for repairing or reconstructing a joint can require securely fastening a surgical implant to a hone. For example, shoulder joint reconstruction can require fixing a glenoid implant to a scapula to reproduce or replicate a glenoid cavity on the scapula. The surgical implant can be securely fastened to the hone in a variety of ways, including mechanical fasteners and adhesive.
To better illustrate the system disclosed herein, a non-limiting list of examples is provided here:
Example 1 is a central augment for use in a shoulder replacement procedure, the central augment comprising: a body including a glenoid engagement surface shaped to interface with a central portion of a reamed glenoid and a second surface opposite the first curved surface and defining a recess sized to receive a boss of a glenoid component; a protrusion extending from the second surface within the recess, the protrusion sized to be received within a bore defined by the boss of the glenoid component; and a post extending from the glenoid engagement surface, the post sized to be received in a bore formed in the central portion of the glenoid, wherein at least one of the body and the post includes a porous metal coating.
In Example 2, the subject matter of Example 1 optionally includes wherein the first curved surface has a bulbous shape.
In Example 3, the subject matter of any one or more of Examples 1-2 optionally include wherein the first curved surface has a spherical shape.
In Example 4, the subject matter of any one or more of Examples 1-3 optionally include wherein the first curved surface is shaped for a specific patient.
In Example 5, the subject matter of any one or more of Examples 1-4 optionally include wherein the post includes a threaded portion.
In Example 6, the subject matter of any one or more of Examples 1-5 optionally include wherein the post includes a barbed portion.
In Example 7, the subject matter of any one or more of Examples 1-6 optionally include wherein the post is a fluted peg.
In Example 8, the subject matter of any one or more of Examples 1-7 optionally include wherein the recess includes a tapered profile complementary to the portion of the glenoid component.
In Example 9, the subject matter of any one or more of Examples 1-8 optionally include wherein the protrusion includes one or more external threads configured to mate with one or more internal threads disposed within the boss of the glenoid component.
In Example 10, the subject matter of any one or more of Examples 1-9 optionally include wherein at least one of the body and the post includes a porous metal coating.
Example 11 is a modular glenoid system for use in a shoulder replacement procedure, the modular glenoid system comprising: a glenoid component including: an articulation surface, a glenoid engaging surface opposite the articulation surface, and a boss extending from the glenoid engaging surface; and a modular augment including: a first outer surface, a second internal surface opposite the first outer surface and defining a recess sized to receive the boss, a post, the first outer surface forming a dome and shaped to interface with a reamed portion of a glenoid, the post extending from the first outer surface and sized to be received in a bore created in the glenoid; and a protrusion extending from the second internal surface and sized to be received within a bore in the boss.
In Example 12, the subject matter of Example 11 optionally includes wherein the protrusion includes a male threaded portion and the bore includes a female threaded portion for receiving the male threaded portion.
In Example 13, the subject matter of any one or more of Examples 11-12 optionally include wherein the glenoid component includes a plurality of pegs spaced about the boss.
In Example 14, the subject matter of any one or more of Examples 11-13 optionally include wherein the modular augment is selected from a plurality of modular augments, each of the plurality of modular augments sized to complement a different sized central defect.
Example 15 is a method for replacing a glenoid component, the method comprising: reaming a central portion of a glenoid; implanting a modular augment into the central portion of the glenoid, the modular augment including a first curved surface, a second curved surface opposite the first curved surface and defining a recess sized to receive a boss extending from an augment engaging surface of a glenoid component, the first curved surface including a post extending therefrom sized to be received in a bore created in the boss of the glenoid component; and implanting the glenoid component into the glenoid, the glenoid component coupled to the modular augment via the post and the bore created in the boss.
In Example 16, the subject matter of Example 15 optionally includes selecting the modular augment from a plurality of modular augments, each of the plurality of modular augments sized to complement a different sized central defect.
In Example 17, the subject matter of any one or more of Examples 15-16 optionally include wherein the modular augment is patient specific.
In Example 18, the subject matter of any one or more of Examples 15-17 optionally include wherein implanting the modular augment and the glenoid component occur simultaneously.
In Example 19, the subject matter of Example 18 optionally includes screwing the post into the bore of the boss of the glenoid component.
In Example 20, the subject matter of any one or more of Examples 15-19 optionally include wherein the modular augment is press fitted with the glenoid component.
In Example 21, the modular augment or modular glenoid system of any one of or any combination of Examples 1-20 is optionally configured such that all elements or options recited are available to use or select from.
The above-mentioned and other features and advantages of this disclosure, and the manner of attaining them, will become more apparent and the disclosure itself will be better understood by reference to the following description of embodiments taken in conjunction with the accompanying drawings, wherein:
Corresponding reference characters indicate corresponding parts throughout the several views. The exemplifications set out herein illustrate exemplary embodiments of the disclosure, and such exemplifications are not to be construed as limiting the scope of the disclosure any manner.
As used herein, the following directional definitions apply. Anterior and posterior mean nearer the front or nearer the rear of the body, respectively, proximal and distal mean nearer to or further from the root of a structure, respectively, and medial and lateral mean nearer the sagittal plane or further from the sagittal plane, respectively. The sagittal plane is an imaginary vertical plane through the middle of the body that divides the body into right and left halves. In addition, the terms implant and prosthesis, and variations thereof, can be used interchangeably.
Through injury, trauma, aging, or other degenerative conditions a joint, such as the shoulder, can become damaged or otherwise less mobile. In addition, the injury, trauma, aging, or other condition can cause repeated injury. For example, an injury to a shoulder can cause a central defect or other damage to a glenoid socket. The central defect or other damage can cause the humeral head to more easily become dislocated from the glenoid socket. For instance, a person can suffer from a glenoid chondral defect that can lead to or be caused by glenohumeral dislocation.
As disclosed herein, a modular augment can be used to repair a central defect. The modular augment can include a body and a post that extends from the body. The post and body portions can be implanted into a central portion of a glenoid socket to assist in repairing a central defect. Addressing a central defect with the modular augment can allow for existing bone around a central portion of the glenoid to be saved or otherwise remain undisturbed during a surgical procedure.
The central defect can be in any bony anatomy. For example, the central defect can be in a shoulder joint, a hip joint, or the hand or wrist. For instance, in a shoulder joint the central defect can be in the glenoid. In a hip joint the central defect can be in an acetabular fossa. In a hand, the central defect can be in a base of a metacarpal bone or phalanges bones.
With reference to
The modular augment 204 can include a body 206 and a post 208 that extends from the body 206. As shown in
The porous metal layer 210 (or porous components) can allow for bone ingrowth to further secure the modular augment 204 to the glenoid. The porous metal layer 210 can be a highly porous, three-dimensional metallic structure that can incorporate one or more of a variety of biocompatible metals such as but not limited to titanium, a titanium alloy, cobalt chromium, cobalt chromium molybdenum, tantalum, a tantalum alloy, niobium, or alloys of tantalum and niobium with one another or with other metals. Such structures are particularly suited for contacting bone and/or soft tissue, and in this regard, can be useful as bone substitutes and other implants and implant components that are receptive to cell and tissue ingrowth, for example, by allowing bony tissue or other tissue to grow into the porous structure over time to enhance fixation (e.g., osseointegration) between the structure and surrounding bodily structures. In accordance with examples disclosed herein, an open porous metal structure, or a portion thereof, can have a bulk porosity as low as 55%, 65%, or 75% or as high as 80%, 85%, or 90%, or within any range defined between any pair of the foregoing values, and in this regard, such structures can provide lightweight, yet strong porous implants. Certain porous metal structures, despite having such high porosities, are capable of withstanding extreme mechanical loads at the time of implantation and over long periods of time, for example, where a highly porous, three-dimensional metallic structure is forcefully impacted and press fit into a bone, by itself or connected to another implant, and maintains its shape during impaction and following many months or years of service in the body. Such structures can be manufactured according to any suitable technique or process. An example of an open porous metal structure is produced using Trabecular Metal® Technology available from Zimmer, Inc., of Warsaw, Ind. Trabecular Metal® is a trademark of Zimmer, Inc. Such a material can be formed from a reticulated vitreous carbon foam substrate which is infiltrated and coated with a biocompatible metal, such as tantalum, by a chemical vapor deposition (“CVD”) process in the manner disclosed in detail in U.S. Pat. No. 5,282,861 and in Levine, B. R., et al., “Experimental and Clinical Performance of Porous Tantalum in Orthopedic Surgery”, Biomaterials 27 (2006) 4671-4681, the disclosures of which are expressly incorporated herein by reference.
In some instances, a highly porous, three-dimensional metallic structure can be fabricated using a selective laser sintering (SLS) or other additive manufacturing-type process such as direct metal laser sintering or electron beam melting. In one example, a three-dimensional porous article can be produced in layer-wise fashion from a laser-fusible powder, e.g., a single-component metal powder, which can be deposited one layer at a time. The powder can be fused, remelted or sintered, by the application of laser energy that is directed to portions of the powder layer corresponding to a cross section of the article. After the fusing of the powder in each layer, an additional layer of powder can be deposited, and a further fusing step can be carried out, with fused portions or lateral layers fusing so as to fuse portions of previous laid layers until a three-dimensional article is complete. In certain examples, a laser can selectively fuse powdered material by scanning cross-sections generated from a 3-D digital description of the article, e.g., from a CAD file or scan data, on the surface of a powder bed. Complex geometries can be created using such techniques, and in some instances, net shape and near net shape implants can be constructed. In some examples, a non-porous or essentially non-porous base substrate can provide a foundation upon which a three-dimensional porous structure can be built and fused thereto using a selective laser sintering (SLS) or other additive manufacturing-type process. Such substrates can incorporate one or more of a variety of biocompatible metals such as any of those disclosed herein.
Generally, a highly porous, three-dimensional metallic structure will include a large plurality of ligaments that define open voids (e.g., pores) or channels between the ligaments. The open spaces between the ligaments form a matrix of continuous channels having few or no dead ends, such that growth of soft tissue and/or bone through the open porous metal is substantially uninhibited. According to some aspects of the present disclosure, exterior surfaces of an open porous metal structure can feature terminating ends of the above-described ligaments. Such terminating ends can be referred to as struts, and they can generate a high coefficient of friction along an exposed porous metal surface. Such features can impart an enhanced affixation ability to an exposed porous metal surface for adhering to bone and soft tissue. Also, when such highly porous metal structures are coupled to an underlying substrate, a small percentage of the substrate can be in direct contact with the ligaments of the highly porous structure, for example, approximately 15%, 20%, or 25%, of the surface area of the substrate can be in direct contact with the ligaments of the highly porous structure.
A highly porous, three-dimensional metallic structure can be fabricated such that it comprises a variety of densities in order to selectively tailor the structure for particular orthopedic applications, for example, by matching the structure to surrounding natural tissue in order to provide an improved matrix for tissue ingrowth and mineralization. Such structures can be isotropic or anisotropic. In this regard, according to certain examples, an open porous metal structure can be fabricated to have a substantially uniform porosity, density, void (pore) size, pore shape, and/or pore orientation throughout, or to have one or more features such as porosity, density, void (pore) size, pore shape, and/or pore orientation being varied within the structure, or within a portion thereof. For example, an open porous metal structure can have a different pore size, pore shape, and/or porosity at different regions, layers, and surfaces of the structure. The ability to selectively tailor the structural properties of the open porous metal enables, for example, tailoring of the structure for distributing stress loads throughout the surrounding tissue and promoting specific tissue ingrowth within the open porous metal. In some instances, a highly porous, three-dimensional metallic structure, once formed, can be infiltrated and coated with one or more coating materials such as biocompatible metals such as any of those disclosed herein.
In addition to a porous metal, the post 208 or the porous metal layer 210 can form threads 602 (see
The body 206 can include a curved surface 212 and a glenoid component engaging surface 214. The curved surface 212 can match a profile of a reamed portion of the glenoid. For example, a reamer can have a hemispherical profile or other bulbous shape that corresponds to a hemispherical or bulbous shape of the curved surface 212. In addition, the curved surface 212 can be patient specific. For instance, a surgeon can use images of a patient's glenoid and specify a shape of the curved surface 212 to match the anatomy of the patient. The modular augment 204 can then be manufactured with the curved surface 212 matched to the specific contours (reamed or natural) for a particular patient.
The glenoid component engaging surface 214 can match a profile of the glenoid component 202. For example, the glenoid component 202 can include a boss 402 that projects from a glenoid engaging surface 216. Stated another way, the glenoid component engaging surface 214 can define a recess sized to receive a portion of the glenoid component 202 (e.g., the boss 402) or, as shown in
By having the modular augment 204 and the glenoid component 202 as separate components of the modular glenoid system 200, the glenoid component 202 can be adjusted or replaced without disturbing the modular augment 204. For example, after the modular glenoid system 200 is implanted, a revision might be needed at a later date. Because of the modular nature of the glenoid system 200, the glenoid component 202 can be removed without removing the modular augment 204.
In addition, the modular augment 204 can be utilized with glenoid components 202 of varying size and configurations. For example, the modular augment 204 and the glenoid component 202 can be components of a system that includes a plurality of modular augments and glenoid components. During a surgical procedure, a surgeon can select a modular augment 204 that best conforms to a size, shape, or other aspect of a central defect. The protrusion 406 and the glenoid component engaging surface 214 of the various modular augments can be a standard size and boss 402 and bore 404 of the various glenoid components can be a standard size such that modular augments and glenoid components can be mixed and matched to create an implant more tailored to a patient.
For example, the central defect of a patient can be small. Thus, a surgeon can select a modular augment 204 that is of similar size and shape of the central defect. By being able to select an appropriately sized modular augment 204, the amount of bone needed to be removed during a reaming process or other disturbance to the glenoid can be minimized. This can improve healing times as well as minimize patient pain and discomfort.
The modular augment 204 can be made of polymers, ceramics, metallic materials, or any combination thereof. For example, modular augment 204 can be injection molded from a polymer, such as a vitamin E stabilized polymer and coated with the porous metal layer 210 as indicated above. In addition, the porous metal layer 210 can coat only the post 208, the curved surface 212, or any portions thereof.
The modular augment 204 can be manufactured using any number of manufacturing techniques or a combination of techniques. For example, the body 206 can be an injection molded polymer that can attach to a metallic portion that forms the post 208 and the protrusion 406, which can be machined from a billet material.
The glenoid component 202 can include one or more pegs 218. The pegs 218 can extend from the glenoid engaging surface 216. For example, the pegs 218 can extend from the glenoid engaging surface 216 such that one or more of the pegs 218 is parallel to the post 208. In addition, one or more of the pegs 218 can extend from the glenoid engaging surface 216 such that one or more of the pegs 218 is not parallel to the post 208.
The pegs 218 can be monolithic to the glenoid component 202 or separate components that can be removably coupled to the glenoid component 202. For example, a body 222 of the glenoid component 202 can include one or more holes that can receive the pegs 218. The pegs 218 can be threaded, press fit, snap fit, etc. into the one or more holes. In addition, the body 222 of the glenoid component 202 and the pegs 218 can be formed of a continuous material (i.e., monolithic). For example, the body 222 and the pegs 218 can be formed from a polymer and during a single operation such as injection or direct compression molding.
The pegs 218 can be spaced about the modular augment 204 in any configuration, and any number of pegs 218 can be provided. As shown in
The pegs 218 can include fins or flutes 224. The number of flutes 224 can vary between pegs. For instance, one peg can have three flutes and another peg can have two flutes. The pegs 218 and flutes 225 can be made of or coated with a porous metal as disclosed herein. The pegs 218 can all be the same length, or one of the pegs 218 can have a length that is different from at least one other peg 218.
The glenoid component 202 can include an articulation surface 226. The articulation surface 226 can allow a humeral head (natural bone or prosthetic) to articulate and allow for a range of motion of a humerus. The contour of the articulation surface 226 can be patient-specific. For example, a surgeon can use images of a patient's glenoid to specify a shape and contour of the glenoid component 202 and the articulation surface 226. The glenoid component can then be manufactured with the articulation surface 226 tailored to a patient.
As disclosed herein, the glenoid component 202 can be selected from a plurality of glenoid components during a surgical procedure. For example, once a patient's glenoid and humeral head are exposed, a surgeon can examine the glenoid and humeral head and select a glenoid component from one of the plurality of glenoid components that most closely matches a geometry of the patient's glenoid. For instance, the surgeon can select a glenoid component that has a glenoid articulating surface with a curvature similar to that of the patient.
From stage 502, the method 500 can proceed to stage 504 where the modular augment can be assembled. In an example, prior to implantation, the modular augment providing the best anatomical fit can be selected from a plurality of modular augments having different sizes, shapes, dimensions, or the like. The glenoid component can be press fitted to the modular augment or screwed into the modular augment as disclosed herein.
From stage 504, the method 500 can proceed to stage 506 where the assembled implant can be implanted. As disclosed herein, the modular augment can be press fit, snap fit, screwed, or otherwise fastened to the reamed portion of the glenoid. During implantation, the post of the modular augment can be inserted into the glenoid to anchor the modular augment to the glenoid. Implanting the glenoid component can include securing the glenoid component to the modular augment. In addition, the various pegs of the glenoid component can be embedded into the glenoid during the implanting process.
Alternatively, the modular augment and the glenoid component can be implanted independently of one another. For example, the modular implant can be implanted prior to implanting the glenoid component. Once the modular augment is implanted the glenoid component can be implanted and attached to both the glenoid and the modular augment.
The modular augment and the glenoid component can be patient-specific or part of an implantation system. For example, during the surgical procedure, the surgeon can select the modular augment, the glenoid component, or both, from a plurality of modular augments and a plurality of glenoid components based on observations and measurements of the patient's glenoid during surgery.
It will be readily understood to those skilled in the art that various other changes in the details, material, and arrangements of the parts and method stages which have been described and illustrated in order to explain the nature of the inventive subject matter can be made without departing from the principles and scope of the inventive subject matter as expressed in the subjoined claims.
This application is a U.S. National Stage Filing under 35 U.S.C. 371 from International Patent Application Serial No. PCT/US2018/013795, filed Jan. 16, 2018, which published on Jul. 26, 2018 as WO 2018/0136393 A1, which application claims priority to U.S. Provisional Application No. 62/448,547, filed on Jan. 20, 2017, the contents of which are hereby incorporated by reference in their entireties.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2018/013795 | 1/16/2018 | WO | 00 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2018/136393 | 7/26/2018 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
2947308 | Gorman | Aug 1960 | A |
3605123 | Hahn | Sep 1971 | A |
3658056 | Huggler et al. | Apr 1972 | A |
D230429 | Davidson et al. | Feb 1974 | S |
3855638 | Pilliar | Dec 1974 | A |
3871031 | Boutin | Mar 1975 | A |
3891997 | Herbert | Jul 1975 | A |
3903549 | Deyerle | Sep 1975 | A |
3906550 | Rostoker et al. | Sep 1975 | A |
3918102 | Eichler | Nov 1975 | A |
4064567 | Burstein et al. | Dec 1977 | A |
4136405 | Pastrick et al. | Jan 1979 | A |
4164794 | Spector et al. | Aug 1979 | A |
4206516 | Pilliar | Jun 1980 | A |
4216549 | Hillberry et al. | Aug 1980 | A |
4219893 | Noiles | Sep 1980 | A |
4224696 | Murray et al. | Sep 1980 | A |
4404691 | Buning et al. | Sep 1983 | A |
4444061 | Mathias | Apr 1984 | A |
4523587 | Frey | Jun 1985 | A |
4549319 | Meyer | Oct 1985 | A |
4550448 | Kenna | Nov 1985 | A |
4566138 | Lewis et al. | Jan 1986 | A |
4659331 | Matthews et al. | Apr 1987 | A |
4662891 | Noiles | May 1987 | A |
4678470 | Nashef et al. | Jul 1987 | A |
4693721 | Ducheyne | Sep 1987 | A |
4711639 | Grundei | Dec 1987 | A |
4718909 | Brown | Jan 1988 | A |
4735625 | Davidson | Apr 1988 | A |
4778473 | Matthews et al. | Oct 1988 | A |
4789663 | Wallace et al. | Dec 1988 | A |
4790852 | Noiles | Dec 1988 | A |
4822366 | Bolesky | Apr 1989 | A |
4827919 | Barbarito et al. | May 1989 | A |
4828565 | Duthoit et al. | May 1989 | A |
4834759 | Spotomo et al. | May 1989 | A |
4840632 | Kampner | Jun 1989 | A |
4865607 | Witzel et al. | Sep 1989 | A |
4878919 | Pavlansky et al. | Nov 1989 | A |
4883448 | Kobayashi et al. | Nov 1989 | A |
4883488 | Bloebaum et al. | Nov 1989 | A |
4888021 | Forte et al. | Dec 1989 | A |
4936859 | Morscher et al. | Jun 1990 | A |
4938769 | Shaw | Jul 1990 | A |
4944757 | Martinez et al. | Jul 1990 | A |
4950298 | Gustilo et al. | Aug 1990 | A |
4960427 | Noiles | Oct 1990 | A |
4964865 | Burkhead et al. | Oct 1990 | A |
4986833 | Worland | Jan 1991 | A |
4988359 | Frey et al. | Jan 1991 | A |
5019103 | Van Zile et al. | May 1991 | A |
5032134 | Lindwer | Jul 1991 | A |
5059196 | Coates | Oct 1991 | A |
5092897 | Forte | Mar 1992 | A |
5108446 | Wagner et al. | Apr 1992 | A |
5133771 | Duncan et al. | Jul 1992 | A |
5152797 | Luckman et al. | Oct 1992 | A |
5156626 | Broderick et al. | Oct 1992 | A |
5163966 | Norton et al. | Nov 1992 | A |
5176711 | Grimes | Jan 1993 | A |
5192329 | Christie et al. | Mar 1993 | A |
5197488 | Kovacevic | Mar 1993 | A |
5211664 | Tepic et al. | May 1993 | A |
5222984 | Forte | Jun 1993 | A |
5226915 | Bertin | Jul 1993 | A |
5246459 | Elias | Sep 1993 | A |
5370693 | Kelman et al. | Jun 1994 | A |
5356414 | Cohen et al. | Oct 1994 | A |
5356629 | Sander et al. | Oct 1994 | A |
5358527 | Forte | Oct 1994 | A |
5358530 | Hodorek | Oct 1994 | A |
5376123 | Klaue et al. | Dec 1994 | A |
5387241 | Hayes | Feb 1995 | A |
5405394 | Davidson | Apr 1995 | A |
5413604 | Hodge | May 1995 | A |
5443512 | Parr et al. | Aug 1995 | A |
5462563 | Shearer et al. | Oct 1995 | A |
5480444 | Incavo | Jan 1996 | A |
5480445 | Burkinshaw | Jan 1996 | A |
5489311 | Cipolletti | Feb 1996 | A |
5507830 | DeMane et al. | Apr 1996 | A |
5510396 | Prewett et al. | Apr 1996 | A |
5531791 | Wolfinbarger, Jr. | Jul 1996 | A |
5549685 | Hayes | Aug 1996 | A |
5571198 | Drucker | Nov 1996 | A |
5591233 | Kelman et al. | Jan 1997 | A |
5593448 | Dong | Jan 1997 | A |
5609645 | Vinciuerra | Mar 1997 | A |
5658338 | Tullos et al. | Aug 1997 | A |
5658349 | Brooks et al. | Aug 1997 | A |
5662158 | Caldarise | Sep 1997 | A |
5683467 | Pappas | Nov 1997 | A |
5702447 | Walch et al. | Dec 1997 | A |
5702478 | Tomier | Dec 1997 | A |
5702483 | Kwong | Dec 1997 | A |
5734959 | Krebs et al. | Mar 1998 | A |
5766256 | Oudard et al. | Jun 1998 | A |
5782925 | Collazo et al. | Jul 1998 | A |
5782929 | Sederholm | Jul 1998 | A |
5788976 | Bradford | Aug 1998 | A |
5800551 | Williamson et al. | Sep 1998 | A |
5824103 | Williams et al. | Oct 1998 | A |
5858020 | Johnson et al. | Jan 1999 | A |
5871548 | Sanders et al. | Feb 1999 | A |
5879393 | Whiteside et al. | Mar 1999 | A |
5910172 | Penenberg | Jun 1999 | A |
5931409 | Nulle et al. | Aug 1999 | A |
5957979 | Beckman et al. | Sep 1999 | A |
5958314 | Draenert | Sep 1999 | A |
5972368 | McKay | Oct 1999 | A |
5976148 | Charpenet et al. | Nov 1999 | A |
5984968 | Park | Nov 1999 | A |
5993716 | Draenert | Nov 1999 | A |
5997581 | Khalili | Dec 1999 | A |
6008432 | Taylor | Dec 1999 | A |
6013080 | Khalili | Jan 2000 | A |
6039764 | Pottenger et al. | Mar 2000 | A |
6042612 | Voydeville | Mar 2000 | A |
6053945 | O'Neil et al. | Apr 2000 | A |
6074423 | Lawson | Jun 2000 | A |
6074424 | Perrone, Jr. et al. | Jun 2000 | A |
6080195 | Colleran et al. | Jun 2000 | A |
6117175 | Bosredon | Sep 2000 | A |
6126691 | Kasra et al. | Oct 2000 | A |
6136029 | Johnson et al. | Oct 2000 | A |
6139581 | Engh et al. | Oct 2000 | A |
6139584 | Ochoa et al. | Oct 2000 | A |
6142998 | Smith et al. | Nov 2000 | A |
6162254 | Timoteo | Dec 2000 | A |
6162255 | Oyola | Dec 2000 | A |
6171342 | O'Neil et al. | Jan 2001 | B1 |
6228119 | Ondrla et al. | May 2001 | B1 |
6264699 | Noiles et al. | Jul 2001 | B1 |
6290725 | Weiss et al. | Sep 2001 | B1 |
6294187 | Boyce et al. | Sep 2001 | B1 |
6328764 | Mady | Dec 2001 | B1 |
6355069 | DeCarlo, Jr. et al. | Mar 2002 | B1 |
6364910 | Shultz et al. | Apr 2002 | B1 |
6368352 | Camino et al. | Apr 2002 | B1 |
6379386 | Resch et al. | Apr 2002 | B1 |
6406495 | Schoch | Jun 2002 | B1 |
6423096 | Musset et al. | Jul 2002 | B1 |
6428578 | White | Aug 2002 | B2 |
6447549 | Taft | Sep 2002 | B1 |
6458161 | Gibbs et al. | Oct 2002 | B1 |
6613092 | Kana et al. | Sep 2003 | B1 |
6682568 | Despres, III et al. | Jan 2004 | B2 |
6699293 | White | Mar 2004 | B2 |
6783549 | Stone et al. | Aug 2004 | B1 |
6797006 | Hodorek | Sep 2004 | B2 |
6818019 | Horber | Nov 2004 | B2 |
6843806 | Hayes et al. | Jan 2005 | B2 |
6875218 | Dye et al. | Apr 2005 | B2 |
6875237 | Dye et al. | Apr 2005 | B2 |
6911047 | Rockwood, Jr. et al. | Jun 2005 | B2 |
6926740 | Lewis et al. | Aug 2005 | B2 |
6946001 | Sanford et al. | Sep 2005 | B2 |
6981991 | Ferree | Jan 2006 | B2 |
7105026 | Johnson et al. | Sep 2006 | B2 |
7179295 | Kovacevic | Feb 2007 | B2 |
7179296 | Dooney | Feb 2007 | B2 |
7179297 | McLean | Feb 2007 | B2 |
7179298 | Greenlee | Feb 2007 | B2 |
D538431 | Botha | Mar 2007 | S |
7238208 | Camino | Jul 2007 | B2 |
7264636 | Lewis et al. | Sep 2007 | B2 |
7291174 | German et al. | Nov 2007 | B2 |
7291177 | Gibbs | Nov 2007 | B2 |
7435263 | Barnett et al. | Oct 2008 | B2 |
7713306 | Gibbs | May 2010 | B2 |
D618800 | Mayon et al. | Jun 2010 | S |
7753959 | Berelsman et al. | Jul 2010 | B2 |
7846212 | Lewis et al. | Dec 2010 | B2 |
7892288 | Blaylock et al. | Feb 2011 | B2 |
7892289 | Serafin, Jr. et al. | Feb 2011 | B2 |
8123814 | Meridew et al. | Feb 2012 | B2 |
8382849 | Thomas | Feb 2013 | B2 |
D684693 | Hanssen et al. | Jun 2013 | S |
8506645 | Blaylock et al. | Aug 2013 | B2 |
8535385 | Hanssen et al. | Sep 2013 | B2 |
8696677 | Chavarria et al. | Apr 2014 | B2 |
8728168 | Hanssen et al. | May 2014 | B2 |
8876907 | Baptista et al. | Nov 2014 | B2 |
9044326 | Blaylock et al. | Jun 2015 | B2 |
9192476 | Thomas et al. | Nov 2015 | B2 |
9265614 | Blaylock et al. | Feb 2016 | B2 |
9539096 | Hanssen et al. | Jan 2017 | B2 |
9713532 | Blaylock et al. | Jul 2017 | B2 |
9713533 | Taylor et al. | Jul 2017 | B2 |
10092404 | Hanssen et al. | Oct 2018 | B2 |
10098743 | Hanssen et al. | Oct 2018 | B2 |
10195043 | Taylor et al. | Feb 2019 | B2 |
10201426 | Hanssen et al. | Feb 2019 | B2 |
10646346 | Hanssen et al. | May 2020 | B2 |
10653526 | Hanssen et al. | May 2020 | B2 |
10806587 | Hanssen et al. | Oct 2020 | B2 |
20010037153 | Rockwood, Jr. et al. | Nov 2001 | A1 |
20020072802 | O'Neil et al. | Jun 2002 | A1 |
20020095214 | Hyde, Jr. | Jul 2002 | A1 |
20020120339 | Callaway et al. | Aug 2002 | A1 |
20020151984 | White | Oct 2002 | A1 |
20030055507 | Mcdevitt et al. | Mar 2003 | A1 |
20030065397 | Hanssen et al. | Apr 2003 | A1 |
20030153981 | Wang et al. | Aug 2003 | A1 |
20030163203 | Nycz et al. | Aug 2003 | A1 |
20030183025 | Krstic | Oct 2003 | A1 |
20030204263 | Justin et al. | Oct 2003 | A1 |
20030229398 | Iesaka | Dec 2003 | A1 |
20040034432 | Hughes et al. | Feb 2004 | A1 |
20040049270 | Gewirtz | Mar 2004 | A1 |
20040049284 | German et al. | Mar 2004 | A1 |
20040059424 | Guederian et al. | Mar 2004 | A1 |
20040117024 | Gerbec et al. | Jun 2004 | A1 |
20040122519 | Wiley et al. | Jun 2004 | A1 |
20040162619 | Blaylock et al. | Aug 2004 | A1 |
20040172137 | Blaylock et al. | Sep 2004 | A1 |
20040220674 | Pria | Nov 2004 | A1 |
20050060039 | Cyprien | Mar 2005 | A1 |
20050107882 | Stone et al. | May 2005 | A1 |
20050107883 | Goodfried et al. | May 2005 | A1 |
20050165494 | McLeod et al. | Jul 2005 | A1 |
20050261775 | Baum et al. | Nov 2005 | A1 |
20050278034 | Johnson et al. | Dec 2005 | A1 |
20050283254 | Hayes, Jr. et al. | Dec 2005 | A1 |
20050288795 | Bagga | Dec 2005 | A1 |
20060069443 | Deffenbaugh et al. | Mar 2006 | A1 |
20060069444 | Deffenbaugh | Mar 2006 | A1 |
20060079963 | Hansen | Apr 2006 | A1 |
20060122705 | Morgan | Jun 2006 | A1 |
20060149388 | Smith et al. | Jul 2006 | A1 |
20060200248 | Beguin et al. | Sep 2006 | A1 |
20070055380 | Berelsman et al. | Mar 2007 | A1 |
20070088443 | Hanssen et al. | Apr 2007 | A1 |
20070100458 | Dalla Pria | May 2007 | A1 |
20070129809 | Meridew et al. | Jun 2007 | A1 |
20070142917 | Roche et al. | Jun 2007 | A1 |
20070156246 | Meswania et al. | Jul 2007 | A1 |
20070173948 | Meridew et al. | Jul 2007 | A1 |
20070219637 | Berelsman et al. | Sep 2007 | A1 |
20070219638 | Jones et al. | Sep 2007 | A1 |
20070225817 | Reubelt et al. | Sep 2007 | A1 |
20070225818 | Reubelt et al. | Sep 2007 | A1 |
20070244563 | Roche et al. | Oct 2007 | A1 |
20070244564 | Ferrand et al. | Oct 2007 | A1 |
20080167722 | Metzger et al. | Jul 2008 | A1 |
20080269906 | Iannotti et al. | Oct 2008 | A1 |
20080281430 | Kelman et al. | Nov 2008 | A1 |
20090125113 | Guederian et al. | May 2009 | A1 |
20090149961 | Dallmann | Jun 2009 | A1 |
20090164021 | Dallmann | Jun 2009 | A1 |
20090192621 | Winslow et al. | Jul 2009 | A1 |
20100049327 | Isch et al. | Feb 2010 | A1 |
20100114326 | Winslow | May 2010 | A1 |
20100145452 | Blaylock et al. | Jun 2010 | A1 |
20100228352 | Courtney, Jr. et al. | Sep 2010 | A1 |
20100241235 | Basamania et al. | Sep 2010 | A1 |
20100324691 | Brunnarius | Dec 2010 | A1 |
20110035013 | Winslow et al. | Feb 2011 | A1 |
20110066252 | Hanssen et al. | Mar 2011 | A1 |
20110112651 | Blaylock et al. | May 2011 | A1 |
20110118846 | Katrana et al. | May 2011 | A1 |
20110276144 | Wirth et al. | Nov 2011 | A1 |
20110282403 | Anthony et al. | Nov 2011 | A1 |
20110295382 | Hanssen et al. | Dec 2011 | A1 |
20120109321 | Stone | May 2012 | A1 |
20120130498 | Long | May 2012 | A1 |
20120130499 | Long | May 2012 | A1 |
20120179262 | Metcalfe et al. | Jul 2012 | A1 |
20120221111 | Burkhead, Jr. et al. | Aug 2012 | A1 |
20120239051 | De Wilde et al. | Sep 2012 | A1 |
20120239155 | De Wilde et al. | Sep 2012 | A1 |
20120277880 | Winslow et al. | Nov 2012 | A1 |
20130013078 | Hanssen et al. | Jan 2013 | A1 |
20130013080 | Hanssen et al. | Jan 2013 | A1 |
20130018478 | Hanssen et al. | Jan 2013 | A1 |
20130123929 | Mcdaniel et al. | May 2013 | A1 |
20130144393 | Mutchler et al. | Jun 2013 | A1 |
20130150975 | Iannotti et al. | Jun 2013 | A1 |
20130190881 | Winslow et al. | Jul 2013 | A1 |
20130253658 | Despres et al. | Sep 2013 | A1 |
20130261753 | Lappin et al. | Oct 2013 | A1 |
20130261754 | Anthony et al. | Oct 2013 | A1 |
20130304221 | Blaylock et al. | Nov 2013 | A1 |
20140005789 | Chavarria et al. | Jan 2014 | A1 |
20140031945 | Baptista et al. | Jan 2014 | A1 |
20140039638 | Meridew et al. | Feb 2014 | A1 |
20140074250 | Podolsky et al. | Mar 2014 | A1 |
20140081418 | Hanssen et al. | Mar 2014 | A1 |
20140128983 | Flaherty et al. | May 2014 | A1 |
20140194995 | Koka | Jul 2014 | A1 |
20140249637 | Hanssen et al. | Sep 2014 | A1 |
20140257499 | Winslow et al. | Sep 2014 | A1 |
20140277518 | Iannotti | Sep 2014 | A1 |
20150150688 | Vanasse et al. | Jun 2015 | A1 |
20150250602 | Sikora | Sep 2015 | A1 |
20150257890 | Blaylock et al. | Sep 2015 | A1 |
20150272741 | Taylor et al. | Oct 2015 | A1 |
20150374502 | Hodorek et al. | Dec 2015 | A1 |
20160008138 | Katrana et al. | Jan 2016 | A1 |
20160058560 | Blaylock et al. | Mar 2016 | A1 |
20160151164 | Taylor et al. | Jun 2016 | A1 |
20160184103 | Fonte et al. | Jun 2016 | A1 |
20160262902 | Winslow et al. | Sep 2016 | A1 |
20160270922 | Pressacco | Sep 2016 | A1 |
20160310285 | Kovacs et al. | Oct 2016 | A1 |
20170020675 | Blaylock et al. | Jan 2017 | A1 |
20170281357 | Taylor et al. | Oct 2017 | A1 |
20180256337 | Hanssen et al. | Sep 2018 | A1 |
Number | Date | Country |
---|---|---|
2004203348 | Sep 2005 | AU |
2473633 | Sep 2005 | CA |
102014802 | Apr 2011 | CN |
103519923 | Jan 2014 | CN |
103702627 | Apr 2014 | CN |
107205824 | Sep 2017 | CN |
110191691 | Aug 2019 | CN |
102010044571 | Mar 2012 | DE |
0336774 | Dec 1992 | EP |
0532585 | Apr 2000 | EP |
1004283 | May 2000 | EP |
0863731 | Apr 2001 | EP |
1004283 | Mar 2002 | EP |
1004283 | May 2005 | EP |
1913902 | Apr 2008 | EP |
2130518 | Dec 2009 | EP |
2679199 | Jan 2014 | EP |
2689751 | Jan 2014 | EP |
2822508 | Jan 2015 | EP |
2702651 | Sep 1994 | FR |
2772593 | Jun 1999 | FR |
2937245 | May 2012 | FR |
2971416 | Aug 2012 | FR |
2223172 | Apr 1990 | GB |
6169930 | Jun 1994 | JP |
10277069 | Oct 1998 | JP |
2000185062 | Jul 2000 | JP |
2001503283 | Mar 2001 | JP |
2001526573 | Dec 2001 | JP |
2004016822 | Jan 2004 | JP |
2005246036 | Sep 2005 | JP |
2009513285 | Apr 2009 | JP |
2016513498 | May 2016 | JP |
2017536195 | Dec 2017 | JP |
WO-9730661 | Aug 1997 | WO |
WO-9852499 | Nov 1998 | WO |
WO-9932053 | Jul 1999 | WO |
WO-0205732 | Jan 2002 | WO |
WO-2007109319 | Sep 2007 | WO |
WO-2009089581 | Jul 2009 | WO |
WO-2013134333 | Sep 2013 | WO |
WO-20150130006 | Sep 2015 | WO |
WO-2015148655 | Oct 2015 | WO |
WO-2016089642 | Jun 2016 | WO |
WO-2018136393 | Jul 2018 | WO |
Entry |
---|
US 5,536,414 A, 10/1994, Cohen et al. (withdrawn) |
“Canadian Application Serial No. 3,051,099, Office Action dated Oct. 5, 2020”, 3 pgs. |
“European Application Serial No. 18742374.4, Extended European Search Report dated Nov. 10, 2020”, 3 pgs. |
“Japanese Application Serial No. 2017-529340, Response filed Aug. 20, 2020 to Final Notification of Reasons for Refusal dated Jun. 8, 2020”, w/ English claims, 18 pgs. |
“Japanese Application Serial No. 2019-539802, Notification of Reasons for Refusal dated Oct. 20, 2020”, w/ English Translation, 11 pgs. |
U.S. Appl. No. 29/369,066, filed Sep. 1, 2020, Prosthetic Implant Support Structure. |
U.S. Appl. No. 14/085,040 U.S. Pat. No. 9,539,096, filed Nov. 20, 2013, Methods for Supporting a Prosthetic Implant in a Patient. |
U.S. Appl. No. 14/278,916, filed May 15, 2014, Prosthetic Implant Support Structure. |
U.S. Appl. No. 15/978,686, filed May 14, 2018, Posthetic Implant Support Structure. |
U.S. Appl. No. 10/225,774, filed Aug. 22, 2002, Prosthetic Implant Support Structure. |
U.S. Appl. No. 11/560,276 U.S. Pat. No. 10,201,426, filed Nov. 15, 2006, Prosthetic Implant Support Structure. |
U.S. Appl. No. 12/946,132 U.S. Pat. No. 8,728,168, filed Nov. 15, 2010, Prosthetic Implant Support Structure. |
U.S. Appl. No. 13/205,163 U.S. Pat. No. 8,535,385, filed Aug. 8, 2011, Prosthetic Implant Support Structure. |
U.S. Appl. No. 12/702,861, filed Feb. 9, 2010, Prosthetic Implant Support Structure. |
U.S. Appl. No. 29/379,094 U.S. Pat No. D684,693, filed Nov. 15, 2010, Prosthetic Implant Support Structure. |
U.S. Appl. No. 13/619,091 U.S. Pat. No. 10/098,743, filed Sep. 14, 2012, Prosthetic Implant Support Structure. |
U.S. Appl. No. 13/619,134 U.S. Pat. No. 10,092,404, filed Sep. 14, 2012, Prosthetic Implant Support Structure. |
U.S. Appl. No. 13/619,190, filed Sep. 14, 2012, Prosthetic Implant Support Structure. |
U.S. Appl. No. 14/226,051, filed Mar. 26, 2014, Press-Fit Glenoid With Peripheral Compression Pegs. |
U.S. Appl. No. 14/558,024 U.S. Pat. No. 9,713,533, filed Dec. 2, 104, In-Line Pegged Hybrid Glenoid. |
U.S. Appl. No. 15/629,794 U.S. Pat. No. 10,195,042, filed Jun. 22, 2017, In-Line Pegged Hybrid Glenoid. |
“U.S. Appl. No. 10/225,774,Advisory Action dated Oct. 26, 2005”,3 pgs. |
“U.S. Appl. No. 10/225,774, Examiner Interview Summary dated Mar. 17, 2005”, 4 pgs. |
“U.S. Appl. No. 10/225,774, Final Office Action dated Jun. 6, 2005”, 9 pgs. |
“U.S. Appl. No. 10/225,774, Final Office Action dated Aug. 17, 2016”, 8 pgs. |
“U.S. Appl. No. 10/225,774, Non-Final Office Action dated Feb. 8, 2006”,6 pgs. |
“U.S. Appl. No. 10/225,774, Non-Final Office Action dated Jun. 30, 2004”,5 pgs. |
“U.S. Appl. No. 10/225,774, Non-Final Office Action dated Dec. 8, 2004”,6 pgs. |
“U.S. Appl. No. 10/225,774, Response filed Mar. 7, 2005 to Non-Final Office Action dated Dec. 8, 2004”, 21 pgs. |
“U.S. Appl. No. 10/225,774, Response filed Apr. 16, 2004 to Restriction Requirement dated Mar. 17, 2004”, 1 pg. |
“U.S. Appl. No. 10/225,774, Response filed Jun. 7, 2006 to Non-Final Office Action dated Feb. 8, 2016”, 21 pgs. |
“U.S. Appl. No. 10/225,774, Response filed Sep. 20, 2004 to Non-Final Office Action dated Jun. 30, 2004”, 14 pgs. |
“U.S. Appl. No. 10/225,774, Response filed Oct. 6, 2005 to Final Office Action dated Jun. 6, 2005”, 21 pgs. |
“U.S. Appl. No. 10/225,774, Response filed Nov. 15, 2006 to Final Office Action dated Aug. 17, 2006”, 1 pg. |
“U.S. Appl. No. 10/225,774, Restriction Requirement dated Mar. 17, 2004”, 6 pgs. |
“U.S. Appl. No. 10/780,378, Final Office Action dated Aug. 20, 2010”, 7 pgs. |
“U.S. Appl. No. 10/780,378, Final Office Action dated Aug. 21, 2008”, 8 pgs. |
“U.S. Appl. No. 10/780,378, Final Office Action dated Aug. 27, 2007”, 7 pgs. |
“U.S. Appl. No. 10/780,378, Non Final Office Action dated Feb. 2, 2009”, 7 pgs. |
“U.S. Appl. No. 10/780,378, Non Final Office Action dated Mar. 30, 2007”, 7 pgs. |
“U.S. Appl. No. 10/780,378, Non Final Office Action dated Dec. 12, 2007”, 8 pgs. |
“U.S. Appl. No. 10/780,378, Preliminary Amendment filed Jun. 1, 2004”, 20 pgs. |
“U.S. Appl. No. 10/780,378, Response filed Jan. 4, 2007 to Restriction Requirement dated Dec. 4, 2006”, 1 pg. |
“U.S. Appl. No. 10/780,378, Response filed May 28, 2008 to Non-Final Office Action dated Dec. 12, 2007”, 11 pgs. |
“U.S. Appl. No. 10/780,378, Response filed Jun. 15, 2007 to Non-Final Office Action dated Mar. 30, 2007”, 7 pgs. |
“U.S. Appl. No. 10/780,378, Response filed Jun. 24, 2009 to Non-Final Office Action dated Feb. 2, 2009”, 15 pgs. |
“U.S. Appl. No. 10/780,378, Response filed Sep. 15, 2006 to Restriction Requirement dated Aug. 25, 2006”, 1 pg. |
“U.S. Appl. No. 10/780,378, Response filed Oct. 31, 2007 to Final Office Action dated Aug. 27, 2007”, 8 pgs. |
“U.S. Appl. No. 10/780,378, Response filed Nov. 12, 2008 to Final Office Action dated Aug. 21, 2008”, 10 pgs. |
“U.S. Appl. No. 10/780,378, Response filed Dec. 22, 2009 to Restriction Requirement dated Oct. 22, 2009”, 2 pgs. |
“U.S. Appl. No. 10/780,378, Restriction Requirement dated Aug. 25, 2006”, 6 pgs. |
“U.S. Appl. No. 10/780,378, Restriction Requirement dated Oct. 22, 2009”, 7 pgs. |
“U.S. Appl. No. 10/780,378, Restriction Requirement dated Dec. 4, 2006”, 6 pgs. |
“U.S. Appl. No. 10/794,721, Final Office Action dated Jan. 16, 2008”, 8 pgs. |
“U.S. Appl. No. 10/794,721, Final Office Action dated Jan. 16, 2009”, 6 pgs. |
“U.S. Appl. No. 10/794,721, Final Office Action dated May 6, 2010”, 8 pgs. |
“U.S. Appl. No. 10/794,721, Non Final Office Action dated Jul. 8, 2008”, 6 pgs. |
“U.S. Appl. No. 10/794,721, Non Final Office Action dated Aug. 3, 2007”, 7 pgs. |
“U.S. Appl. No. 10/794,721, Non Final Office Action dated Nov. 2, 2006”, 7 pgs. |
“U.S. Appl. No. 10/794,721, Non-Final Office Action dated Jun. 15, 2009”,9 pgs. |
“U.S. Appl. No. 10/794,721, Notice of Allowance dated Oct. 14, 2010”,6 pgs. |
“U.S. Appl. No. 10/794,721, Response filed Feb. 2, 2007 to Non Final Office Action dated Nov. 2, 2006”, 7 pgs. |
“U.S. Appl. No. 10/794,721, Response filed Apr. 14, 2009 to Final Office Action dated Jan. 16, 2009”, 8 pgs. |
“U.S. Appl. No. 10/794,721, Response filed Jun. 16, 2008 to Final Office Action dated Jan. 16, 2008”, 8 pgs. |
“U.S. Appl. No. 10/794,721, Response filed Sep. 28, 2009 to Non Final Office Action dated Jun. 15, 2009”, 10 pgs. |
“U.S. Appl. No. 10/794,721, Response filed Oct. 6, 2010 to Final Office Action dated May 6, 2010”, 6 pgs. |
“U.S. Appl. No. 10/794,721, Response filed Oct. 8, 2008 to Non Final Office Action dated Jul. 8, 2008”, 8 pgs. |
“U.S. Appl. No. 10/794,721, Response filed Nov. 8, 2007 to Non Final Office Action dated Aug. 3, 2007”, 7 pgs. |
“U.S. Appl. No. 10/794,721, Supplemental Response filed Feb. 8, 2010 to Non Final Office Action dated Jan. 12, 2010”, 2 pgs. |
“U.S. Appl. No. 10/794,721, Supplemental Response filed May 18, 2007 to Non Final Office Action dated Nov. 2, 2006”, 7 pgs. |
“U.S. Appl. No. 11/560,276,Appeal Brief filed Oct. 27, 2016”, 68 pgs. |
“U.S. Appl. No. 11/560,276,Appeal Decision mailed Apr. 16, 2018”, 16 pgs. |
“U.S. Appl. No. 11/560,276,Appellants' Reply Brieffiled Feb. 1, 2017 to Examiner's Answer dated Dec. 1, 2016”, 15 pgs. |
“U.S. Appl. No. 11/560,276, Examiner Interview Summary dated Jan. 18, 2012”, 4 pgs. |
“U.S. Appl. No. 11/560,276, Examiner Interview Summary dated Jun. 5, 2012”, 3 pgs. |
“U.S. Appl. No. 11/560,276, Final Office Action dated Feb. 26, 2016”, 17 pgs. |
“U.S. Appl. No. 11/560,276, Final Office Action dated Mar. 27, 2012”, 8 pgs. |
“U.S. Appl. No. 11/560,276, Final Office Action dated May 1, 2015”, 16 pgs. |
“U.S. Appl. No. 11/560,276, Final Office Action dated Jun. 25, 2014”, 10 pgs. |
“U.S. Appl. No. 11/560,276, Final Office Action dated Oct. 8, 2010”, 6 pgs. |
“U.S. Appl. No. 11/560,276, Final Office Action dated Oct. 17, 2013”, 12 pgs. |
“U.S. Appl. No. 11/560,276, Non Final Office Action dated Jan. 22, 2014”, 10 pgs. |
“U.S. Appl. No. 11/560,276, Non Final Office Action dated Mar. 3, 2010”, 8 pgs. |
“U.S. Appl. No. 11/560,276, Non Final Office Action dated Aug. 11, 2011”, 6 pgs. |
“U.S. Appl. No. 11/560,276, Non Final Office Action dated Sep. 25, 2015”, 16 pgs. |
“U.S. Appl. No. 11/560,276, Non Final Office Action dated Dec. 5, 2014”, 14 pgs. |
“U.S. Appl. No. 11/560,276, Notice of Allowance dated Jul. 13, 2018”,6 pgs. |
“U.S. Appl. No. 11/560,276, Notice of Allowance dated Oct. 2, 2018”,6 pgs. |
“U.S. Appl. No. 11/560,276, Response filed Jan. 25, 2016 to Non-Final Office Action dated Sep. 25, 2015”, 33 pgs. |
“U.S. Appl. No. 11/560,276, Response filed Feb. 7, 2011 to Final Office Action dated Oct. 8, 2010”, 10 pgs. |
“U.S. Appl. No. 11/560,276, Response filed Feb. 13, 2012 to Non Final Office Action dated Aug. 11, 2011”, 13 pgs. |
“U.S. Appl. No. 11/560,276, Response filed Apr. 6, 2015 to Non-Final Office Action dated Dec. 5, 2014”, 16 pgs. |
“U.S. Appl. No. 11/560,276, Response filed May 22, 2014 to Non Final Office Action dated Jan. 22, 2014”, 10 pgs. |
“U.S. Appl. No. 11/560,276, Response filed Jun. 27, 2012 to Final Office Action dated Mar. 27, 2012”, 12 pgs. |
“U.S. Appl. No. 11/560,276, Response filed Aug. 2, 2010 to Non Final Office Action dated Mar. 3, 2010”, 12 pgs. |
“U.S. Appl. No. 11/560,276, Response filed Sep. 1, 2015 to Final Office Action dated May 1, 2015”, 28 pgs. |
“U.S. Appl. No. 11/560,276, Response filed Oct. 21, 2009 to Restriction Requirement dated Aug. 21, 2009”, 12 pgs. |
“U.S. Appl. No. 11/560,276, Response filed Oct. 27, 2014 to Final Office Action dated Jun. 25, 2014”, 13 pgs. |
“U.S. Appl. No. 11/560,276, Response filed Dec. 17, 2013 to Final Office Action dated Oct. 17, 2013”, 11 pgs. |
“U.S. Appl. No. 11/560,276, Restriction Requirement dated Aug. 21, 2009”, 7 pgs. |
“U.S. Appl. No. 12/886,297, Examiner Interview Summary dated May 6, 2013”, 3 pgs. |
“U.S. Appl. No. 12/886,297, Final Office Action dated Nov. 16, 2013”, 6 pgs. |
“U.S. Appl. No. 12/886,297, Non Final Office Action dated Apr. 22, 2013”, 6 pgs. |
“U.S. Appl. No. 12/886,297, Non Final Office Action dated Jun. 21, 2012”, 10 pgs. |
“U.S. Appl. No. 12/886,297, Notice of Allowance dated Feb. 22, 2013”,10 pgs. |
“U.S. Appl. No. 12/886,297, Notice of Allowance dated Jun. 26, 2013”,10 pgs. |
“U.S. Appl. No. 12/886,297, Preliminary Amendment filed Sep. 20, 2010”, 10 pgs. |
“U.S. Appl. No. 12/886,297, Response filed May 7, 2012 to Restriction Requirement dated Mar. 6, 2012”, 2 pgs. |
“U.S. Appl. No. 12/886,297, Response filed Oct. 22, 2012 to Non Final Office Action dated Jun. 21, 2012”, 19 pgs. |
“U.S. Appl. No. 12/886,297, Restriction Requirement dated Mar. 6, 2012”, 6 pgs. |
“U.S. Appl. No. 12/946,132, Examiner Interview Summary dated Jun. 5, 2012”, 3 pgs. |
“U.S. Appl. No. 12/946,132, Final Office Action dated Jul. 25, 2012”, 12 pgs. |
“U.S. Appl. No. 12/946,132, Non Final Office Action dated Mar. 28, 2012”, 10 pgs. |
“U.S. Appl. No. 12/946,132, Non Final Office Action dated Oct. 11, 2013”, 7 pgs. |
“U.S. Appl. No. 12/946,132, Notice of Allowance dated Mar. 27, 2014”, 6 pgs. |
“U.S. Appl. No. 12/946,132, Response filed Feb. 11, 2014 to Non-Final Office Action dated Oct. 11, 2013”, 19 pgs. |
“U.S. Appl. No. 12/946,132, Response filed Jun. 27, 2012 to Non Final Office Action dated Mar. 28, 2012”, 15 pgs. |
“U.S. Appl. No. 12/946,132, Response filed Sep. 6, 2011 to Restriction Requirement dated Aug. 23, 2011”, 8 pgs. |
“U.S. Appl. No. 12/946,132, Response filed Sep. 24, 2012 to Final Office Action dated Jul. 25, 2012”, 16 pgs. |
“U.S. Appl. No. 12/946,132, Restriction Requirement dated Aug. 23, 2011”, 8 pgs. |
“U.S. Appl. No. 13/007,225, Examiner Interview Summary dated May 30, 2013”, 23 pgs. |
“U.S. Appl. No. 13/007,225, Final Office Action dated Apr. 18, 2013”, 10 pgs. |
“U.S. Appl. No. 13/007,225, Final Office Action dated Jun. 25, 2014”, 11 pgs. |
“U.S. Appl. No. 13/007,225, Non Final Office Action dated Jan. 29, 2014”, 11 pgs. |
“U.S. Appl. No. 13/007,225, Non Final Office Action dated Nov. 19, 2012”, 9 pgs. |
“U.S. Appl. No. 13/007,225, Non Final Office Action dated Dec. 11, 2014”, 6 pgs. |
“U.S. Appl. No. 13/007,225, Notice of Allowance dated Apr. 6, 2015”,10 pgs. |
“U.S. Appl. No. 13/007,225, Preliminary Amendment filed Jan. 14, 2011”, 4 pgs. |
“U.S. Appl. No. 13/007,225, Response filed Mar. 3, 2015 to Non-Final Office ACtion dated Dec. 11, 2014”, 13 pgs. |
“U.S. Appl. No. 13/007,225, Response filed Mar. 12, 2013 to Non-Final Office Action dated Nov. 19, 2012”, 13 pgs. |
“U.S. Appl. No. 13/007,225, Response filed May 29, 2014 to Non Final Office Action dated Jan. 29, 2014”, 12 pgs. |
“U.S. Appl. No. 13/007,225, Response filed Jul. 18, 2013 to Final Office Action dated Apr. 18, 2013”, 15 pgs. |
“U.S. Appl. No. 13/007,225, Response filed Oct. 22, 2012 to Restriction Requirement dated Sep. 20, 2012”, 10 pgs. |
“U.S. Appl. No. 13/007,225, Response filed Oct. 27, 2014 to Final Office Action dated Jun. 25, 2014”, 16 pgs. |
“U.S. Appl. No. 13/007,225, Restriction Requirement dated Sep. 20, 2012”, 8 pgs. |
“U.S. Appl. No. 13/007,225, Supplemental Preliminary Amendment filed Sep. 23, 2011”, 8 pgs. |
“U.S. Appl. No. 13/205,163, Non Final Office Action dated Apr. 4, 2013”, 8 pgs. |
“U.S. Appl. No. 13/205,163, Notice of Allowance dated Aug. 5, 2013”,9 pgs. |
“U.S. Appl. No. 13/205,163, Preliminary Amendment filed Aug. 8, 2011”, 8 pgs. |
“U.S. Appl. No. 13/205,163, Response filed Feb. 21, 2013 to Restriction Requirement dated Jan. 24, 2013”, 10pgs. |
“U.S. Appl. No. 13/205,163, Response filed Jul. 3, 2013 to Non Final Office Action dated Apr. 4, 2013”, 13 pgs. |
“U.S. Appl. No. 13/205,163, Restriction Requirement dated Jan. 24, 2013”, 6 pgs. |
“U.S. Appl. No. 13/416,857, Non Final Office Action dated Feb. 25, 2013”, 17 pgs. |
“U.S. Appl. No. 13/416,857, Response filed May 24, 2013 to Non Final Office Action dated Feb. 25, 2013”, 15 pgs. |
“U.S. Appl. No. 13/619,091, Advisory Action dated Sep. 17, 2014”, 3 pgs. |
“U.S. Appl. No. 13/619,091, Appeal Brief filed Feb. 11, 2016”, 103 pgs. |
“U.S. Appl. No. 13/619,091, Appeal Brief filed Dec. 19, 2016”, 113 pgs. |
“U.S. Appl. No. 13/619,091, Appeal Decision dated Apr. 27, 2018”, 32 pgs. |
“U.S. Appl. No. 13/619,091, Examiner Interview Summary dated Sep. 8, 2014”, 3 pgs. |
“U.S. Appl. No. 13/619,091, Final Office Action dated Mar. 10, 2015”, 18 pgs. |
“U.S. Appl. No. 13/619,091, Final Office Action dated May 9, 2014”, 10 pgs. |
“U.S. Appl. No. 13/619,091, Final Office Action dated Oct. 11, 2016”, 21 pgs. |
“U.S. Appl. No. 13/619,091, Final Office Action dated Dec. 2, 2015”, 19 pgs. |
“U.S. Appl. No. 13/619,091, Non Final Office Action dated Jun. 22, 2016”, 22 pgs. |
“U.S. Appl. No. 13/619,091, Non Final Office Action dated Jul. 1, 2015”, 17 pgs. |
“U.S. Appl. No. 13/619,091, Non Final Office Action dated Dec. 4, 2014”, 15 pgs. |
“U.S. Appl. No. 13/619,091, Non Final Office Action dated Dec. 13, 2013”, 11 pgs. |
“U.S. Appl. No. 13/619,091, Notice of Allowance dated Sep. 4, 2018”, 7 pgs. |
“U.S. Appl. No. 13/619,091, Notice of Non-Compliant Amendment dated Jul. 17, 2018”, 2 pgs. |
“U.S. Appl. No. 13/619,091, Preliminary Amendment filed Aug. 26, 2013”, 7 pgs. |
“U.S. Appl. No. 13/619,091, Reply Brief filed Apr. 3, 2017”, 11 pgs. |
“U.S. Appl. No. 13/619,091, Response filed Jan. 21, 2015 to Non-Final Office Action dated Dec. 4, 2014”, 31 pgs. |
“U.S. Appl. No. 13/619,091, Response filed Apr. 14, 2014 to Non-Final OfficeAction dated Dec. 13, 2013”, 13 pgs. |
“U.S. Appl. No. 13/619,091, Response filed Jun. 10, 2015 to Final Office Action dated Mar. 10, 2015”, 32 pgs. |
“U.S. Appl. No. 13/619,091, Response filed Aug. 1, 2018 to Notice of Non-Compliant Amendment dated Jul. 17, 2018”, 17 pgs. |
“U.S. Appl. No. 13/619,091, Response filed Sep. 9, 2014 to Final Office Action dated May 9, 2014”, 12 pgs. |
“U.S. Appl. No. 13/619,091, Response filed Sep. 22, 2016 to Non Final Office Action dated Jun. 22, 2016”, 34 pgs. |
“U.S. Appl. No. 13/619,091, Response filed Oct. 9, 2014 to Advisory Action dated Sep. 17, 2014”, 14 pgs. |
“U.S. Appl. No. 13/619,091, Response filed Nov. 8, 2013 to Restriction Requirement dated Oct. 23, 2013”, 8 pgs. |
“U.S. Appl. No. 13/619,091, Response filed Nov. 10, 2015 to Non-Final Office Action dated Jul. 1, 2015”, 37 pgs. |
“U.S. Appl. No. 13/619,091, Restriction Requirement dated Oct. 23, 2013”, 5 pgs. |
“U.S. Appl. No. 13/619,134, Advisory Action dated Sep. 18, 2014”, 3 pgs. |
“U.S. Appl. No. 13/619,134, Appeal Brief filed Feb. 4, 2016”, 72 pgs. |
“U.S. Appl. No. 13/619,134, Appeal Brief filed Dec. 19, 2016”, 112 pgs. |
“U.S. Appl. No. 13/619,134, Appeal Decision dated May 1, 2018”, 32 pgs. |
“U.S. Appl. No. 13/619,134, Appellant's Reply Brieffiled May 19, 2017”, 14 pgs. |
“U.S. Appl. No. 13/619,134, Examiner's Answer dated Mar. 20, 2017”, 15 pgs. |
“U.S. Appl. No. 13/619,134, Final Office Action dated Mar. 10, 2015”, 20 pgs. |
“U.S. Appl. No. 13/619,134, Final Office Action dated May 8, 2014”, 10 pgs. |
“U.S. Appl. No. 13/619,134, Final Office Action dated Oct. 11, 2106”, 25 pgs. |
“U.S. Appl. No. 13/619,134, Final Office Action dated Dec. 2, 2015”, 21 pgs. |
“U.S. Appl. No. 13/619,134, Non Final Office Action dated Jun. 22, 2016”, 24 pgs. |
“U.S. Appl. No. 13/619,134, Non Final Office Action dated Jul. 6, 2015”, 19 pgs. |
“U.S. Appl. No. 13/619,134, Non Final Office Action dated Dec. 5, 2014”, 18 pgs. |
“U.S. Appl. No. 13/619,134, Non Final Office Action dated Dec. 13, 2013”, 9 pgs. |
“U.S. Appl. No. 13/619,134, Notice of Allowance dated Aug. 29, 2018”,7 pgs. |
“U.S. Appl. No. 13/619,134, Notice of Non-Compliant Amendment dated Jul. 17, 2018”, 2 pgs. |
“U.S. Appl. No. 13/619,134, Response filed Jan. 22, 2015 to Non-Final Office Action dated Dec. 5, 2014”, 32 pgs. |
“U.S. Appl. No. 13/619,134, Response filed Apr. 14, 2014 to Non-Final Office Action dated Dec. 13, 2013”, 11 pgs. |
“U.S. Appl. No. 13/619,134, Response filed Jun. 10, 2015 to Non-Final Office Action dated Mar. 10, 2015”, 33 pgs. |
“U.S. Appl. No. 13/619,134, Response filed Aug. 1, 2018 to Notice of Non-Compliant Amendment dated Jul. 17, 2018”,17 pgs. |
“U.S. Appl. No. 13/619,134, Response filed Sep. 8, 2014 to Final Office Action dated May 8, 2014”, 13 pgs. |
“U.S. Appl. No. 13/619,134, Response filed Sep. 22, 2016 to Non-Final Office Action dated Jun. 22, 2016”, 35 pgs. |
“U.S. Appl. No. 13/619,134, Response filed Oct. 9, 2014 to Advisory Action dated Sep. 18, 2014”, 14 pgs. |
“U.S. Appl. No. 13/619,134, Response filed Nov. 8, 2013 to Restriction Requirement dated Oct. 17, 2013”, 8 pgs. |
“U.S. Appl. No. 13/619,134, Response filed Nov. 10, 2015 to Non Final Office Action dated Jul. 6, 2015”, 39 pgs. |
“U.S. Appl. No. 13/619,134, Restriction Requirement dated Oct. 17, 2013”, 5 pgs. |
“U.S. Appl. No. 13/619,190, Appeal Brief filed Aug. 9, 2017”, 85 pgs. |
“U.S. Appl. No. 13/619,190, Examiner's Answer dated Oct. 3, 2017”, 9 pgs. |
“U.S. Appl. No. 13/619,190, Final Office Action dated Mar. 1, 2016”, 18 pgs. |
“U.S. Appl. No. 13/619,190, Final Office Action dated Apr. 27, 2017”, 17 pgs. |
“U.S. Appl. No. 13/619,190, Final Office Action dated May 12, 2015”, 16 pgs. |
“U.S. Appl. No. 13/619,190, Final Office Action dated Jun. 25, 2014”, 10 pgs. |
“U.S. Appl. No. 13/619,190, Non Final Office Action dated Sep. 25, 2015”, 17 pgs. |
“U.S. Appl. No. 13/619,190, Non Final Office Action dated Oct. 27, 2016”, 14 pgs. |
“U.S. Appl. No. 13/619,190, Non Final Office Action dated Dec. 4, 2014”, 14 pgs. |
“U.S. Appl. No. 13/619,190, Non Final Office Action dated Dec. 18, 2013”, 11 pgs. |
“U.S. Appl. No. 13/619,190, Preliminary Amendment filed Oct. 29, 2012”, 8 pgs. |
“U.S. Appl. No. 13/619,190, Reply Brief filed Nov. 28, 2017”, 16 pgs. |
“U.S. Appl. No. 13/619,190, Response filed Jan. 25, 2016 to Non-Final Office Action dated Sep. 25, 2015”, 35 pgs. |
“U.S. Appl. No. 13/619,190, Response filed Mar. 22, 2017 to Non Final Office Action dated Oct. 27, 2016”, 39 pgs. |
“U.S. Appl. No. 13/619,190, Response filed Apr. 6, 2015 to Non-Final Office Action dated Dec. 4, 2014”, 17 pgs. |
“U.S. Appl. No. 13/619,190, Response filed May 19, 2014 to Non Final Office Action dated Dec. 18, 2013”, 12 pgs. |
“U.S. Appl. No. 13/619,190, Response filed Sep. 1, 2015 to Final Office Action dated May 12, 2015”, 30 pgs. |
“U.S. Appl. No. 13/619,190, Response filed Sep. 1, 2016 to Final Office Action dated Mar. 1, 2016”, 29 pgs. |
“U.S. Appl. No. 13/619,190, Response filed Oct. 27, 2014 to Final Office Action dated Jun. 25, 2014”, 13 pgs. |
“U.S. Appl. No. 13/619,190, Response filed Nov. 18, 2013 to Restriction requirement dated Oct. 18, 2013”, 7 pgs. |
“U.S. Appl. No. 13/619,190, Restriction Requirement dated Oct. 18, 2013”, 7 pgs. |
“U.S. Appl. No. 13/619,190, Supplemental Preliminary Amendment filed Apr. 15, 2013”, 8 pgs. |
“U.S. Appl. No. 13/944,441, Final Office Action dated Sep. 17, 2015”, 7 pgs. |
“U.S. Appl. No. 13/944,441, Non Final Office Action dated Apr. 20, 2015”, 12 pgs. |
“U.S. Appl. No. 13/944,441, Notice of Allowance dated Oct. 14, 2015”, 8 pgs. |
“U.S. Appl. No. 13/944,441, Preliminary Amendment filed Jul. 19, 2013”, 8 pgs. |
“U.S. Appl. No. 13/944,441, Response filed Mar. 30, 2015 to Restriction Requirement dated Feb. 2, 2015”, 8 pgs. |
“U.S. Appl. No. 13/944,441, Response filed Aug. 20, 2015 to Non Final Office Action dated Apr. 20, 2015”, 16 pgs. |
“U.S. Appl. No. 13/944,441, Response filed Oct. 5, 2015 to Final Office Action dated Sep. 17, 2015”, 8 pgs. |
“U.S. Appl. No. 13/944,441, Restriction Requirement dated Feb. 2, 2015”, 6 pgs. |
“U.S. Appl. No. 14/085,040, Final Office Action dated Nov. 12, 2015”, 14 pgs. |
“U.S. Appl. No. 14/085,040, Non Final Office Action dated Mar. 28, 2016”, 10 pgs. |
“U.S. Appl. No. 14/085,040, Non Final Office Action dated Jul. 21, 2015”, 12 pgs. |
“U.S. Appl. No. 14/085,040, Notice of Allowance dated Aug. 31, 2016”,6 pgs. |
“U.S. Appl. No. 14/085,040, Response filed Mar. 7, 2016 to Final Office Action dated Nov. 12, 2015”, 7 pgs. |
“U.S. Appl. No. 14/085,040, Response filed Jun. 22, 2015 to Restriction Requirement dated Apr. 22, 2015”, 8 pgs. |
“U.S. Appl. No. 14/085,040, Response filed Jul. 28, 2016 to Non Final Office Action dated Mar. 28, 2016”, 11 pgs. |
“U.S. Appl. No. 14/085,040, Response filed Oct. 21, 2015 to Non Final Office Action dated Jul. 21, 2016”, 34 pgs. |
“U.S. Appl. No. 14/085,040, Restriction Requirement dated Apr. 22, 2015”, 6 pgs. |
“U.S. Appl. No. 14/226,051, Final Office Action dated Nov. 6, 2015”, 10 pgs. |
“U.S. Appl. No. 14/226,051, Non Final Office Action dated Apr. 3, 2015”, 16 pgs. |
“U.S. Appl. No. 14/266,051, Response filed Aug. 13, 2015 to Non Final Office Action dated Apr. 3, 2015”, 11 pgs. |
“U.S. Appl. No. 14/278,916, Appeal Brief filed Aug. 18, 2017”, 77 pgs. |
“U.S. Appl. No. 14/278,916, Examiner's Answer dated Oct. 3, 2017”, 13 pgs. |
“U.S. Appl. No. 14/278,916, Final Office Action dated Sep. 26, 2016”, 11 pgs. |
“U.S. Appl. No. 14/278,916, Non Final Office Action dated Apr. 4, 2017”, 15 pgs. |
“U.S. Appl. No. 14/278,916, Non Final Office Action dated May 11, 2015”, 9 pgs. |
“U.S. Appl. No. 14/278,916, Non Final Office Action dated May 25, 2016”, 13 pgs. |
“U.S. Appl. No. 14/278,916, Non Final Office Action dated Dec. 9, 2015”, 10 pgs. |
“U.S. Appl. No. 14/278,916, Preliminary Amendment filed Jul. 9, 2014”, 4 pgs. |
“U.S. Appl. No. 14/278,916, Reply Brief filed Nov. 28, 2017”, 17 pgs. |
“U.S. Appl. No. 14/278,916, Response filed Mar. 22, 2017 to Final Office Action dated Sep. 26, 2016”, 37 pgs. |
“U.S. Appl. No. 14/278,916, Response filed May 9, 2016 to Final Office Action dated Dec. 9, 2015”, 14 pgs. |
“U.S. Appl. No. 14/278,916, Response filed Sep. 10, 2015 to Non Final Office Action dated May 11, 2015”, 11 pgs. |
“U.S. Appl. No. 14/278,916, Supplemental Preliminary Amendment filed Jul. 18, 2014”, 7 pgs. |
“U.S. Appl. No. 14/558,024, Examiner Interview Summary dated Dec. 21, 2016”, 3 pgs. |
“U.S. Appl. No. 14/558,024, Final Office Action dated Sep. 1, 2016”, 15 pgs. |
“U.S. Appl. No. 14/558,024, Non Final Office Action dated Jan. 15, 2016”, 12 pgs. |
“U.S. Appl. No. 14/558,024, Notice of Allowance dated Feb. 15, 2017”, 11 pgs. |
“U.S. Appl. No. 14/558,024, Notice of Allowance dated Apr. 24, 2017”, 8 pgs. |
“U.S. Appl. No. 14/558,024, Response filed Jun. 14, 2016 to Non Final Office Action dated Jan. 15, 2016”, 11 pgs. |
“U.S. Appl. No. 14/558,024, Response filed Dec. 30, 2016 to Final Office Action dated Sep. 1, 2016”, 10 pgs. |
“U.S. Appl. No. 14/722,701, Advisory Action dated Nov. 9, 2016”, 3 pgs. |
“U.S. Appl. No. 14/722,701, Final Office Action dated Sep. 15, 2016”, 12 pgs. |
“U.S. Appl. No. 14/722,701, Non Final Office Action dated May 6, 2016”, 18 pgs. |
“U.S. Appl. No. 14/722,701, Non Final Office Action dated Dec. 1, 2016”, 8 pgs. |
“U.S. Appl. No. 14/722,701, Notice of Allowance dated Mar. 22, 2017”, 9 pgs. |
“U.S. Appl. No. 14/722,701, Preliminary Amendment filed Jun. 16, 2015”, 9 pgs. |
“U.S. Appl. No. 14/722,701, PTO Response to Rule 312 Communication dated May 24, 2017”, 2 pgs. |
“U.S. Appl. No. 14/722,701, Response filed Feb. 24, 2017 to Non-Final Office Action dated Dec. 1, 2016”, 12 pgs. |
“U.S. Appl. No. 14/722,701, Response filed Aug. 3, 2016 to Non Final Office Action dated May 6, 2016”, 15 pgs. |
“U.S. Appl. No. 14/722,701, Response filed Oct. 31, 2016 to Final Office Action dated Sep. 15, 2016”, 14 pgs. |
“U.S. Appl. No. 14/722,701, Response filed Nov. 11, 2016 to Final Office Action dated Sep. 15, 2016”, 14 pgs. |
“U.S. Appl. No. 14/936,929, Advisory Action dated Jun. 23, 2017”, 3 pgs. |
“U.S. Appl. No. 14/936,929, Final Office Action dated May 23, 2017”, 13 pgs. |
“U.S. Appl. No. 14/936,929, Non Final Office Action dated Feb. 15, 2017”, 12 pgs. |
“U.S. Appl. No. 14/936,929, Non Final Office Action dated Jul. 26, 2017”, 12 pgs. |
“U.S. Appl. No. 14/936,929, Preliminary Amendment filed Nov. 11, 2015”, 7 pgs. |
“U.S. Appl. No. 14/936,929, Response filed Jan. 20, 2017 to Restriction Requirement dated Dec. 14, 2016”, 7 pgs. |
“U.S. Appl. No. 14/936,929, Response filed May 4, 2017 to Non Final Office Action dated Feb. 15, 2017”, 9 pgs. |
“U.S. Appl. No. 14/936,929, Response filed Jun. 14, 2017 to Final Office Action dated May 23, 2017”, 9 pgs. |
“U.S. Appl. No. 14/936,929, Response filed Sep. 18, 2017 to Non Final Office Action dated Jul. 26, 2017”, 10 pgs. |
“U.S. Appl. No. 14/936,929, Restriction Requirement dated Dec. 14, 2016”, 6 pgs. |
“U.S. Appl. No. 15/285,689, Preliminary Amendment filed Oct. 6, 2016”, 12 pgs. |
“U.S. Appl. No. 15/285,689, Supplemental Preliminary Amendment filed May 10, 2017”, 10 pgs. |
“U.S. Appl. No. 15/629,794, Examiner Interview Summary dated Jul. 20, 2018”, 3 pgs. |
“U.S. Appl. No. 15/629,794, Final Office Action dated Apr. 19, 2018”, 19 pgs. |
“U.S. Appl. No. 15/629,794, Non Final Office Action dated Nov. 3, 2017”, 15 pgs. |
“U.S. Appl. No. 15/629,794, Notice of Allowance dated Sep. 19, 2018”,14 pgs. |
“U.S. Appl. No. 15/629,794, Response filed Mar. 2, 2018 to Non Final Office Action dated Nov. 3, 2017”, 15 pgs. |
“U.S. Appl. No. 15/629,794, Response filed Jul. 19, 2018 to Final Office Action dated Apr. 19, 2018”, 10 pgs. |
“U.S. Appl. No. 15/926,794, Preliminary Amendment filed Jun. 26, 2017”,8 pgs. |
“U.S. Appl. No. 15/978,686, Preliminary Amendment filed Jun. 29, 2018”, 6 pgs. |
“U.S. Appl. No. 15/978,686, Supplemental Preliminary Amendment filed Jul. 5, 2018”, 9 pgs. |
“U.S. Appl. No. 29/379,094, Application filed Nov. 15, 2010”, 6 pgs. |
“U.S. Appl. No. 29/379,094, Notice of Allowance dated Feb. 28, 2013”, 12 pgs. |
“U.S. Appl. No. 29/379,094, Response filed Nov. 21, 2012 to Restriction Requirement dated Oct. 23, 2012”, 4 pgs. |
“U.S. Appl. No. 29/379,094, Restriction Requirement dated Oct. 23, 2012”, 7 pgs. |
“Australian Application No. 2004203348, Office Action dated Jan. 13, 2010”, 3 pgs. |
“Australian Application Serial No. 2015355366, First Examination Report dated May 31, 2019”, 3 pgs. |
“Australian Application Serial No. 2018210296, First Examination Report dated Sep. 17, 2019”, 3 pgs. |
“Canadian Application No. 2,473,633, Office Action dated Mar. 12, 2010”, 3 pgs. |
“Canadian Application Serial No. 2,969,745, Office Action dated Aug. 19, 2019”, 6 pgs. |
“Chinese Application Serial No. 201580071660.1, Decision of Rejection dated Aug. 19, 2019”, w/ English Transaltion, 18 pgs. |
“Chinese Application Serial No. 201580071660.1, Office Action dated Mar. 14, 2019”, W/English Translation, 15 pgs. |
“Chinese Application Serial No. 201580071660.1, Office Action dated Jul. 3, 2018”, w/ English translation, 24 pgs. |
“Chinese Application Serial No. 201580071660.1, Response filed May 14, 2019 to Office Action dated Mar. 14, 2019”, w/ English claims, 12 pgs. |
“Chinese Application Serial No. 201580071660.1, Response filed Nov. 9, 2018 to Office Action dated Jun. 3, 2018”, w/ English claims, 12 pgs. |
“European Application No. 04254352.0, European Search Report dated Jun. 22, 2005”, 3 pgs. |
“European Application Serial No. 04254352.0, Examination Notification Art. 94(3) dated Mar. 10, 2014”, 5 pgs. |
“European Application Serial No. 04254352.0, Examination Notification Art. 94(3) dated Apr. 22, 2013”, 5 pgs. |
“European Application Serial No. 04254352.0, Response filed Sep. 2, 2013 to Examination Notification Art. 94(3) dated Apr. 22, 2013”, 10 pgs. |
“European Application Serial No. 13715785.5, Decision to Grant dated Feb. 4, 2016”, 2 pgs. |
“European Application Serial No. 13715785.5, Office Action dated Sep. 7, 2015”, 26 pgs. |
“European Application Serial No. 13715785.5, Response filed May 27, 2015 to Communication pursuant to Rules161(2) and 162 EPC dated Nov. 20, 2014”, 22 pgs. |
“European Application Serial No. 15808304.8, Response filed Feb. 20, 2018 to Action dated Aug. 10, 2018”, 13 pgs. |
“ForbesMagazineRanksZimmerHoldingsAmongthe ‘Best Managed Companiesin America’”, PR Newswire, (Jan. 23, 2004), 2 pgs. |
“International Application Serial No. PCT/US2013/029251, International Preliminary Report on Patentability dated Sep. 18, 2014”, 9 pgs. |
“International Application Serial No. PCT/US2013/029251, International Search Report dated Jun. 19, 2013”, 5 pgs. |
“International Application Serial No. PCT/US2013/029251, Written Opinion dated Jun. 19, 2013”, 7 pgs. |
“International Application Serial No. PCT/US2015/022471, International Preliminary Report on Patentability dated Oct. 6, 2016”, 10 pgs. |
“International Application Serial No. PCT/US2015/022471, International Search Report dated Jul. 28, 2015”, 5 pgs. |
“International Application Serial No. PCT/US2015/022471, Written Opinion dated Jul. 28, 2015”, 8 pgs. |
“International Application Serial No. PCT/US2015/062070, International Preliminary Report on Patentability dated Jun. 15, 2017”, 9 pgs. |
“International Application Serial No. PCT/US2015/062070, International Search Report dated Feb. 12, 2016”, 4 pgs. |
“International Application Serial No. PCT/US2015/062070, Written Opinion dated Feb. 12, 2016”, 7 pgs. |
“International Application Serial No. PCT/US2018/013795, International Preliminary Report on Patentability dated Aug. 1, 2019”, 9 pgs. |
“International Application Serial No. PCT/US2018/013795, International Search Report dated Mar. 12, 2018”, 2 pgs. |
“International Application Serial No. PCT/US2018/013795, Written Opinion dated Mar. 12, 2018”, 7 pgs. |
“Japanese Application No. 2004-216179, Office Action dated May 26, 2009”, (W/ English Translation), 8 pgs. |
“Orthopaedic Salvage System Femoral/Tibial Augmentation”, BiometOrthopedics, Inc., Product Brochure, (2003, 2004), 12 pgs. |
“ZimmerTrabecular Metal Cone”, Zimmer, Inc., (2004), 2 pgs. |
Neer, Charles S., et al., “Glenoid Bone-Grafting in Total Shoulder Arthroplasty”, The Journal of Bone and JointSurgery, vol. 70-A, No. 8,, (Sep. 1998), pp. 1154-1162. |
Walch, Giles, et al., “Morphological Study ofthe Glenoid in Primary Glenohumeral Osteoarthritis”, The Journal of Arthroplasty, 14(6), (1999), 756-760. |
“Japanese Application Serial No. 2017-529340, Notification of Reasons for Refusal dated Nov. 15, 2019”, with English translation, 9 pages. |
“Canadian Application Serial No. 2,969,745, Response filed Nov. 19, 2019 to Office Action dated Aug. 19, 2019”, 16 pages. |
“U.S. Appl. No. 15/978,686, Non Final Office Action dated Dec. 19, 2019”, 12 pages. |
“U.S. Appl. No. 14/278,916, Appeal Decision dated Jan. 2, 2020”, 13 pages. |
“U.S. Appl. No. 13/619,190, Appeal Decision dated Jan. 2, 2020”, 14 pages. |
“Canadian Application Serial No. 2,969,745, Office Action dated Nov. 28, 2019”, 6 pages. |
“Japanese Application Serial No. 2017-529340, Response filed Jan. 14, 2020 to Notification of Reasons for Refusal dated Nov. 15, 2019”, with English claims, 16 pages. |
“U.S. Appl. No. 14/278,916, Notice of Allowance dated Mar. 2, 2020”, 7 pages. |
“U.S. Appl. No. 13/619,190, Notice of Allowance dated Mar. 3, 2020”, 7 pages. |
“U.S. Appl. No. 15/978,686, Response filed Mar. 9, 2020 to Non Final Office Action dated Dec. 19, 2019”, 19 pages. |
“Australian Application Serial No. 2018210296, Response filed Mar. 17, 2020 to First Examination Report dated Sep. 17, 2019”, 17 pages. |
“U.S. Appl. No. 15/978,686, Final Office Action dated Mar. 23, 2020”, 6 pages. |
“European Application Serial No. 18742374.4, Response to Communication pursuant to Rules 161(2) and 162 EPC filed Mar. 20, 2020”, 10 pages. |
“Canadian Application Serial No. 2,969,745, Response filed Mar. 26, 2020 to Office Action dated Nov. 28, 2019”, 3 pages. |
“U.S. Appl. No. 14/278,916, Supplemental Notice of Allowability dated Apr. 22, 2020”, 4 pages. |
“U.S. Appl. No. 15/978,686, Response filed May 20, 2020 to Final Office Action dated Mar. 23, 2020”, 12 pages. |
“U.S. Appl. No. 15/978,686, Notice of Allowance dated Jun. 16, 2020”, 6 pages. |
“Japanese Application Serial No. 2017-529340, Final Notification of Reasons for Refusal dated Jun. 9, 2020”, with English translation, 8 pages. |
“Canadian Application Serial No. 3,051,099, Response filed Feb. 15, 2021 to Office Action dated Oct. 5, 2020”, 13 pgs. |
“Chinese Application Serial No. 201880007640.1, Office Action dated Oct. 30, 2020”, (W/ English Translation), 20 pgs. |
“Chinese Application Serial No. 201880007640.1, Response filed Feb. 26, 2021 to Office Action dated Oct. 30, 2020”, (W/ English Claims), 12 pgs. |
“Japanese Application Serial No. 2019-539802, Response filed Jan. 19, 2021 to Notification of Reasons for Refusal dated Oct. 20, 2020”, (W/ English Claims), 11 pgs. |
“U.S. Appl. No. 17/324,555, Preliminary Amendment filed May 19, 21”, 3 pages. |
“Canadian Application Serial No. 3,051,099, Office Action dated May 20, 21”, 4 pages. |
Number | Date | Country | |
---|---|---|---|
20190336293 A1 | Nov 2019 | US |
Number | Date | Country | |
---|---|---|---|
62448547 | Jan 2017 | US |